Skip to content
Screener

Monte Rosa Therapeutics, Inc. GLUE D&A

D&A at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$594M-41.2%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$2.26M+0.6%
Arvinas logo
ArvinasARVN
$700K0.0%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$2.03M-2.6%
Vor Biopharma logo
Vor BiopharmaVOR
$28K-96.6%
Biohaven logo
BiohavenBHVN
$2.37M+5.3%

Other financials

Income statement

See full
Revenue$9.0M-61.3%
Operating income-$49.1M-216%
Net income-$43.4M-253%
EPS (diluted)-$0.43-187%

Balance sheet

See full
Cash & equivalents$90.1M+29.8%
Total debt$38.0M-7.6%
Total equity$487.3M+81.8%
Total assets$691.2M+92.2%

Cash flow

See full
Operating cash flow-$44.1M-27.1%
CapEx$4.7M+179%
Free cash flow-$48.8M-34.1%

Valuation

See full
Market cap$1.33B+395%
Enterprise value$1.28B+432%
P/S46.2×+44.7×

Profitability

See full
Operating margin-633%—
Net margin-560.8%—
FCF margin-111.7%-125pp

Returns & leverage

See full
Return on equity-42.7%—
Debt / equity0.1×-0.1×
Current ratio10.6×+3.4×

Where this comes from

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:09 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336711
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Depreciation expense$1,911$2,125$3,943$4,173

Item 1. Financial Statements

FAQ

What is Monte Rosa Therapeutics, Inc.'s D&A?
Monte Rosa Therapeutics, Inc. (GLUE) reported D&A of $1.91M in Q2 2026.
How has Monte Rosa Therapeutics, Inc.'s D&A changed year-over-year?
Monte Rosa Therapeutics, Inc.'s D&A decreased by 10.1% year-over-year, from $2.13M to $1.91M.
What is the long-term trend for Monte Rosa Therapeutics, Inc.'s D&A?
Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s D&A has grown at a 41.5% compound annual growth rate (CAGR), from $2.08M to $8.36M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Ask your AI about Monte Rosa Therapeutics, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude